Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | BAX | Q07812 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28072263 | 0.85 | LTA4H (0.55) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL8155454 | 0.85 | LTA4H (0.43) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL61732 | 0.83 | LTA4H (0.57) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL9450784 | 0.81 | LTA4H (0.42) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL6154747 | 0.81 | CYP3A4 (0.42) | LTA4HNR1H2BAXESR1ESR2 | |
| SCHEMBL920289 | 0.80 | TEAD4 (0.47) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL919392 | 0.80 | LTA4H (0.59) | LTA4HMEN1KMT2APARP10TSHR | |
| SCHEMBL157734 | 0.80 | SOS1 (0.40) | LTA4HNR1H2BAXMEN1KMT2A | |
| SCHEMBL511009 | 0.80 | MAOA (0.47) | LTA4HMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL4909322 | 0.80 | MAPT (0.47) | LTA4HNR1H2BAXMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | LTA4H 2659/4885NR1H2 4459/4885BAX 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.